Live
- Big e-commerce firms to adopt Safety Pledge on National Consumer Day
- Cop ends life over torture by wife, father-in-law in Bengaluru
- Indian Constitution longest and most beautiful, Kiren Rijiju lauds its inclusive character
- BSNL's Rs 333 Plan Challenges Airtel and Jio with 1300GB Data: Details
- PM Modi's appeal to buy Khadi garments leads to huge demand in Bihar's Samastipur
- Mohammad Amir announces retirement from international cricket
- Chandrababu supports One Nation, One Election System, says elections in 2029
- Cong not pursuing politics of vengeance: D. K. Shivakumar on Covid 'scam' FIR
- Mexican consulates to strengthen support for nationals in face of US deportation
- Minister Meghwal to table ‘One Nation, One Election’ Bill in Lok Sabha on Monday
Zika drug shows promise in mice
BioCryst Pharmaceuticals Inc said on Monday a dose of its experimental antiviral drug improved survival rates in mice infected with the Zika virus in a preclinical study. Two doses of the drug, BCX443, were tested against a placebo and an oral antiviral called ribavarin for their effect on survival of immune-deficient mice infected with Zika.
BioCryst Pharmaceuticals Inc said on Monday a dose of its experimental antiviral drug improved survival rates in mice infected with the Zika virus in a preclinical study. Two doses of the drug, BCX443, were tested against a placebo and an oral antiviral called ribavarin for their effect on survival of immune-deficient mice infected with Zika.
Seven out of eight mice that received the "standard" dose survived but none of the other mice that received either a low dose, the placebo or ribavirin were alive after 28 days. The study was conducted at Utah State University under an ongoing program run by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health. The mosquito-borne Zika virus has been linked to brain damage in thousands of babies in Brazil. There is no proven vaccine or treatment for the virus.
